Citigroup Lowers Insulet (NASDAQ:PODD) Price Target to $345.00

Insulet (NASDAQ:PODD) had its price target dropped by equities researchers at Citigroup from $380.00 to $345.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Citigroup’s target price suggests a potential upside of 42.63% from the company’s previous close.

A number of other brokerages have also weighed in on PODD. BTIG Research reaffirmed a “buy” rating and set a $380.00 target price on shares of Insulet in a research report on Wednesday. TD Cowen cut shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price on the stock. in a report on Monday, January 26th. Jefferies Financial Group raised their target price on shares of Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Truist Financial lowered their price target on shares of Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Zacks Research lowered shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $354.57.

Insulet Price Performance

Insulet stock opened at $241.89 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.18. The stock has a market cap of $17.03 billion, a price-to-earnings ratio of 69.11, a price-to-earnings-growth ratio of 1.55 and a beta of 1.41. The firm has a 50-day moving average of $272.44 and a two-hundred day moving average of $304.79. Insulet has a 1 year low of $230.05 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The business had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted $1.15 earnings per share. On average, research analysts forecast that Insulet will post 3.92 earnings per share for the current year.

Institutional Trading of Insulet

A number of institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC increased its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet during the fourth quarter worth about $26,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the fourth quarter worth about $28,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in shares of Insulet in the 4th quarter valued at approximately $29,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported a strong Q4: revenue and EPS beats, margin expansion, record Omnipod growth and a bullish 2026 outlook; management also expanded the share‑repurchase program — these operational wins drove the initial post‑earnings rally. Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
• Positive Sentiment: Street reaction includes buy/overweight/outperform reiterations (BTIG reiterated Buy) and headlines noting a gap‑up after the earnings beat, which supported intraday upside earlier this week. BTIG Research Reiterates “Buy” Rating for Insulet Insulet Shares Gap Up Following Earnings Beat
• Neutral Sentiment: Reported short‑interest data is effectively zero/erroneous (0 shares), so there’s no clear short‑squeeze dynamic in play based on the available figures.
• Negative Sentiment: Multiple firms trimmed price targets this week (Raymond James to $355, Citigroup to $345, JPMorgan to $340, Leerink to $360). Although these firms mostly kept Buy/Outperform ratings, the lower targets remove some upside expectations and likely contributed to today’s pullback. Raymond James Adjusts Insulet Price Target Benzinga coverage of analyst target changes

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.